GlassScriptPhysician profile
Andrea B Murray
NPI 1598729394
$11,602.29
in general payments reported to CMS, 2019-2025
69 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $1,299 · 2021: $1,293 · 2022: $2,134 · 2023: $1,836 · 2024: $2,022 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,029.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,251.92 | 2021-2025 | |
| Novo Nordisk INC | $970.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $965.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $925.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $838.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $635.09 | 2019-2025 | Repatha, Otezla, Otezla |
| Allergan, INC. | $452.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.58 | 2019-2025 | Jardiance, Stiolto Respimat |
| Abbott Laboratories | $282.19 | 2022-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $211.33 | 2021-2025 | Zoryve, Seglentis, Livalo |
| Vanda Pharmaceuticals INC. | $190.15 | 2024-2025 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $175.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.61 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $163.09 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $154.79 | 2021-2023 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.